Aclarion, Inc. is a commercial-stage healthcare technology company that has developed a proprietary signal processing software to transform magnetic resonance spectroscopy ('MRS') data into clear biomarkers that can assist surgeons in optimizing clinical treatments. At the core of the technology is the conversion of MRS-produced signals into waveforms that identify the chemical composition of tissues. The biomarkers, developed at the University of California, San Francisco ('UCSF') by Principal Investigator Jeffrey Lotz, and licensed exclusively from the University, form the key inputs for the Company’s proprietary algorithms, which can determine if the scanned intervertebral disc has the chemical and structural characteristics consistent with pain.
